Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
NCT05316480Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in pancreatic neuroendocrine neoplasm (pNEN), sponsored by Fudan University. Planned start May 2022; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic neuroendocrine neoplasm (pNEN)
Beyond the preview
Go deeper on NCT05316480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316480.